We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+49.42%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.93B
AUM Growth
+$917M
Cap. Flow
-$94.3M
Cap. Flow %
-2.4%
Top 10 Hldgs %
73.9%
Holding
131
New
35
Increased
30
Reduced
17
Closed
20

Top Buys

Rank Stock Value
1
ARWR icon
Arrowhead Research
ARWR
+$64.3M
2
CRNX
Crinetics Pharmaceuticals
CRNX
+$54.4M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$26M
4
TNGX icon
Tango Therapeutics
TNGX
+$23.5M
5
MRUS
Merus
MRUS
+$18.5M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$295M
2
CYTK icon
Cytokinetics
CYTK
+$54.7M
3
ARGX icon
argenx
ARGX
+$44.3M
4
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$14.8M
5
FOLD
Amicus Therapeutics
FOLD
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 50.26%
2 Consumer Discretionary 47.87%
3 Miscellaneous 1.15%
4 Technology 0.53%
5 Real Estate 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PEPG icon
76
PepGen
PEPG
$200M
$2.94M 0.07%
+200,000
New +$2.36M
ADAG
77
Adagene
ADAG
$199M
$2.86M 0.07%
1,020,000
+20,000
+2% +$62.3K
GRTS
78
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.65M 0.07%
+1,030,952
New +$2.52M
FATE icon
79
Fate Therapeutics
FATE
$282M
$2.64M 0.07%
+360,311
New +$2.23M
VOR icon
80
Vor Biopharma
VOR
$1.32B
$2.37M 0.06%
50,000
-67,371
-57% -$2.96M
AMZN icon
81
Amazon
AMZN
$2.68T
$2.16M 0.06%
12,000
– –
JANX icon
82
Janux Therapeutics
JANX
$1.01B
$1.88M 0.05%
+50,000
New +$1.09M
NVDA icon
83
NVIDIA
NVDA
$5.12T
$1.72M 0.04%
+19,000
New +$1.38M
AAPL icon
84
Apple
AAPL
$4.84T
$1.71M 0.04%
+10,000
New +$1.82M
DT icon
85
Dynatrace
DT
$15.9B
$1.67M 0.04%
+36,000
New +$1.87M
ADBE icon
86
Adobe
ADBE
$102B
$1.56M 0.04%
+3,100
New +$1.78M
EDU icon
87
New Oriental
EDU
$8.95B
$1.3M 0.03%
+15,000
New +$1.27M
DDOG icon
88
Datadog
DDOG
$82.7B
$1.19M 0.03%
9,600
+2,100
+28% +$264K
KRON
89
DELISTED
Kronos Bio
KRON
$1.1M 0.03%
842,954
– –
GOOGL icon
90
Alphabet (Google) Class A
GOOGL
$4.22T
$1.06M 0.03%
7,000
-800
-10% -$114K
MSFT icon
91
Microsoft
MSFT
$3.69T
$1.05M 0.03%
2,500
– –
SNOW icon
92
Snowflake
SNOW
$114B
$1.05M 0.03%
+6,500
New +$1.26M
INTA icon
93
Intapp
INTA
$2.87B
$1.01M 0.03%
29,500
+12,000
+69% +$471K
IRWD icon
94
Ironwood Pharmaceuticals
IRWD
$671M
$963K 0.02%
110,532
– –
ACHL
95
DELISTED
Achilles Therapeutics
ACHL
$944K 0.02%
755,375
-1,500,000
-67% -$1.62M
PANW icon
96
Palo Alto Networks
PANW
$307B
$852K 0.02%
+6,000
New +$946K
AMD icon
97
Advanced Micro Devices
AMD
$823B
$812K 0.02%
4,500
+2,000
+80% +$350K
PCOR icon
98
Procore
PCOR
$7.99B
$781K 0.02%
9,500
– –
PEGA icon
99
Pegasystems
PEGA
$6.19B
$743K 0.02%
23,000
– –
MDB icon
100
MongoDB
MDB
$30.4B
$717K 0.02%
2,000
+1,000
+100% +$409K
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q1 2024 Portfolio in Review

As of Q1 2024, Artal Group held 131 positions worth $3.93B, up 30% from $3.01B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Artal Group's Q1 2024 filing shows 35 new, 30 increased, 17 reduced and 20 closed positions. Its largest new stake was Crinetics Pharmaceuticals: 1,390,477 shares worth $65.1M. The largest sale was CAVA Group, an estimated $295M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 50% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q1 2024 buy was Crinetics Pharmaceuticals: 1,390,477 shares worth $65.1M.
  • Artal Group added most to Arrowhead Research in Q1 2024, an estimated $64.3M increase.
  • Artal Group's biggest Q1 2024 reduction was CAVA Group, cutting an estimated $295M.
  • Artal Group fully exited argenx in Q1 2024, selling an estimated $44.3M.
  • Artal Group's ten largest holdings make up 74% of its $3.93B portfolio in Q1 2024.
  • Artal Group opened 35 new positions and closed 20 in Q1 2024.
  • Artal Group's portfolio value rose 30% quarter-over-quarter to $3.93B.

Based on Artal Group's 13F filing for Q1 2024, filed 13 May 2024.